Latest Pharmaceutical Revenue News

Page 1 of 1
ALS has delivered a sharp lift in underlying earnings and dividend growth, powered by a 30.4% organic surge in Minerals. But the result also exposes a weaker side of the portfolio, with Life Sciences growth expectations cut to about 3% for FY27.
Victor Sage
Victor Sage
23 Nov 2026
Xenitra has secured a three-year strategic cooperation agreement with JD Health carrying a non-binding A$100 million sales target across prescription medicines, OTC products, FSMP products and health products. The first order is expected in December, with sales targeted to begin in January 2027, but the agreement does not guarantee revenue or impose a penalty if the target is missed.
Victor Sage
Victor Sage
18 Nov 2026
McKesson delivered a strong fiscal second quarter, with revenue up 8% and adjusted diluted EPS rising 18%. The healthcare distributor lifted its full-year adjusted EPS guidance while expanding its specialty-care portfolio through new investments and acquisitions.
Ada Torres
Ada Torres
5 Nov 2026
CONNEQT Health ended the September quarter with just A$501,000 in cash after a A$3.06 million operating outflow, equivalent to 0.16 quarters of funding at the reported burn rate. The company is pursuing R&D-backed debt, inventory finance and an equity raising as Pulse sales recover from an inventory disruption.
Victor Sage
Victor Sage
30 Oct 2026
Mesoblast delivered US$115 million in Ryoncil® revenue in its first full year post-FDA approval, while expanding clinical trials into adult indications and acquiring cutting-edge CAR technology to boost its cell therapy pipeline.
Ada Torres
Ada Torres
30 July 2026
Mesoblast Limited’s Ryoncil® posted US$36 million in Q4 revenue, driving a full-year total of US$115 million, exceeding initial forecasts. The FDA-approved stem cell therapy for pediatric graft-versus-host disease shows robust uptake across US pediatric centres.
Ada Torres
Ada Torres
10 July 2026
ALS Limited reported a 25.8% jump in underlying net profit after tax to AUD 381.2 million for FY26, driven by strong commodity testing demand and margin expansion. The company raised its dividend and advanced major hub lab projects while navigating a post-year-end cyber incident.
Victor Sage
Victor Sage
18 May 2026

Browse the archive

Full archive